First Morning Voided Urinary Gonadotropin Measurements as an Alternative to the GnRH Test

And Demir\textsuperscript{a} Raimo Vuotilainen\textsuperscript{c} Ulf-\texttextbf{Hå}kan Stenman\textsuperscript{b} Leo Dunkel\textsuperscript{d} Kerstin Albertsson-Wikland\textsuperscript{e,f} Ensio Norjavaara\textsuperscript{e,f}

\textsuperscript{a}Children’s Hospital and \textsuperscript{b}Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, and \textsuperscript{c}Department of Pediatrics, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland; \textsuperscript{d}William Harvey Research Institute, Barts and the London, Queen Mary University of London, London, UK; \textsuperscript{e}Department of Pediatrics, Institute of Clinical Sciences, Gothenburg Pediatric Growth Research Center, and \textsuperscript{f}Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Key Words
Luteinizing hormone · Follicle-stimulating hormone · Gonadotropin-releasing hormone test · Hypothalamic-pituitary-gonadal function · Pubertal disorders

Abstract
Aims: We studied whether first morning voided (FMV) urinary gonadotropin measurements could be used as a non-invasive alternative to the GnRH test in the assessment of the hypothalamic-pituitary-gonadal function in children. Methods: In a single-center study, we compared FMV urinary gonadotropin concentrations with basal and GnRH-stimulated serum gonadotropin levels in 274 children and adolescents (78 girls, 196 boys) aged 5–17 years referred for growth and pubertal disorders. The concordance between FMV urinary gonadotropin concentrations and GnRH test results was assessed. Results: FMV urinary LH (U-LH), urinary FSH (U-FSH) and their ratios correlated well with the corresponding basal and GnRH-stimulated serum parameters (r ≥ 0.66, p < 0.001). Receiver operating characteristic curve analyses using urinary and serum LH and FSH concentrations showed that FMV U-LH and U-LH/U-FSH performed equally well as the GnRH test in the differentiation of early puberty (Tanner stage 2) from prepuberty (Tanner stage 1) (area under the curve 0.768–0.890 vs. 0.712–0.858). FMV U-LH and U-LH/U-FSH performed equally well as basal serum LH in predicting a pubertal GnRH test result (area under the curve 0.90–0.93).

Conclusion: FMV U-LH determination can be used for the evaluation of pubertal development and its disorders, reducing the need for invasive GnRH stimulation tests.

Introduction
The onset of pubertal maturation is heralded by increased nighttime secretion of gonadotropins, which is characterized by stronger bursts of LH than FSH secretion. Basal serum LH (S-LH) concentrations reflect the course of pubertal development better than serum FSH (S-FSH) levels, as they increase about 50- to 100-fold between prepuberty and adulthood, while the corresponding increase in S-FSH is about 10-fold \cite{1, 2}. For more than 40 years, the GnRH test has been considered the reference method for assessing the hypothalamic-pituitary-gonadal (HPG) axis function in pubertal disorders \cite{3, 4}, because the previously used radioimmunoassay methods...
did not accurately measure the low basal S-LH and S-FSH levels in prepubertal children. The GnRH test appears to be a better tool for the evaluation of sexual precocity than for delayed puberty [5–10].

Major drawbacks of the GnRH stimulation test are its invasive nature, requirements for adequate hospital facilities and personnel for the test as well as the cost for several S-FSH and S-LH measurements. There have been many attempts to simplify this test, e.g. by determining LH concentration only in a single blood sample obtained at a selected time point [10–12]. As timed urinary gonadotropin excretion reflects integrated gonadotropin secretion, its measurement provides an alternative approach for assessing the function of the HPG axis. Indeed, our previous studies showed that the pubertal developmental stage evaluated by physical examination correlates well with first morning voided (FMV) urinary gonadotropin concentrations [13]. Maesaka et al. [14] have demonstrated that the patterns of monthly urinary gonadotropin excretion in patients with idiopathic precocious puberty are comparable to those in normal subjects matched for pubertal stage.

When determined by a highly sensitive assay, baseline S-LH measurement has been shown to be a sensitive method for the detection of early puberty [1, 15]. Similar findings were recently reported by Pasternak et al. [16], who suggested that basal S-LH concentrations can be used for the evaluation of girls with clinically suspected central precocious puberty. Resende et al. [17] argued, on the basis of their data obtained by immunochemiluminescent assay that boys are unlikely to require a GnRH test to differentiate the pubertal and prepubertal stage, because basal S-LH alone measured by immunochemiluminescent assay was capable of distinguishing these stages. Previous studies have revealed a good correlation between basal S-LH and FMV urinary LH (U-LH) concentrations [13, 18] as well as a clear increase in FMV U-LH concentrations and U-LH/urinary FSH (U-FSH) ratios at the start of puberty [13, 19]. Furthermore, FMV U-LH levels reflect the nocturnal increase in LH secretion and indicate the imminent onset of puberty earlier than daytime S-LH concentrations [13].

The aim of this study was to analyze how well FMV urinary gonadotropin concentration measurements agree with the GnRH stimulation test result, which is the current gold standard for the evaluation of pubertal disorders, and how well they predict the transition from prepuberty to puberty in girls and boys based on clinical, i.e. Tanner, staging.

**Methods**

**Subjects**

FMV urinary as well as serum samples (in conjunction with the same-day GnRH stimulation test) were collected from 274 children and adolescents (78 girls, 196 boys) aged 5–17 years (girls: 6.4–17.4 years; boys: 5.2–17.7 years) with clinically evaluated pubertal stage determined at the Gothenburg Pediatric Growth Research Center (GP-GRC) during a 3.5-year period. Tanner breast stage (B) ≥2 or a testicular volume >3 ml were taken as a definite sign of puberty [20]. The subjects had been referred to the GP-GRC for investigation of growth or pubertal disorders (mainly short or tall stature and suspected precocious or delayed puberty). The GnRH stimulation test was not used to classify these patients.

**Urinary Samples**

Samples from menstruating girls were taken outside their menstrual periods. The subjects emptied their bladders just before bedtime. The entire nighttime (FMV) urine was collected and an aliquot was used for gonadotropin analyses performed within 1–7 days.

**GnRH Test**

After an overnight fast, GnRH (3.5 μg/kg, maximum 100 μg; Relefact, Hoechst AG, Frankfurt, Germany) was injected as an intravenous bolus through an indwelling catheter. Two milliliters of blood were collected immediately before injection (0-min sample) and then 30, 60 and 90 min after the injection. Serum was separated by centrifugation.

**Gonadotropin Assays**

Urinary and serum LH and FSH were determined by time-resolved sandwich fluoroimmunoassays, as previously described [21]. The assay kits were used as recommended by the manufacturer (Delfia hLH Spec and Delfia hFSH; Wallac Oy, Turku, Finland). The assays were calibrated against the WHO Second International Standard for pituitary LH for immunoassay (80/552) and the Second International Reference Preparation of Pituitary FSH/LH (78/549), respectively. The detection limits for S-LH and S-FSH were 0.02 and 0.035 IU/l, respectively, and the intra-assay coefficients of variation for both assays were <2% at levels between 3 and 250 IU/l and about 10% at 0.3 IU/l. The inter-assay coefficient of variation was <3% at 4–18 IU/l for both FSH and LH [22]. The detection limit of the U-FSH assay was 0.018 IU/l and that of the U-LH assay was 0.015 IU/l. The intra- and inter-assay coefficients of variation for the U-FSH assay were 2.3 and 250 IU/l and about 10% at 0.3 IU/l. The inter-assay coefficient of variation was <3% at 4–18 IU/l for both FSH and LH [22]. The detection limit of the U-FSH assay was 0.018 IU/l and that of the U-LH assay was 0.015 IU/l. The intra- and inter-assay coefficients of variation for the U-FSH assay were 2.3 and 250 IU/l and about 10% at 0.3 IU/l. The inter-assay coefficient of variation was <3% at 4–18 IU/l for both FSH and LH [22]. The detection limit of the U-FSH assay was 0.018 IU/l and that of the U-LH assay was 0.015 IU/l. The intra- and inter-assay coefficients of variation for the U-FSH assay were 2.3 and 250 IU/l and about 10% at 0.3 IU/l. The inter-assay coefficient of variation was <3% at 4–18 IU/l for both FSH and LH [22].

**Statistical Analyses**

According to the clinical practice at the GP-GRC, the GnRH stimulation test result was classified as pubertal if the maximum S-LH concentration (S-LH max ) was >5.0 IU/l and the S-LH max /S-FSH max ratio >1.0. For statistical evaluation, FSH and LH concentrations below the detection limit were assigned a value of 0.01 IU/l.
We analyzed the correlation between gonadotropin concentrations and their ratios in FMV urine (U-FSH, U-LH, U-LH/U-FSH) and serum during the GnRH stimulation test (basal FSH = S-FSH, basal LH = S-LH, FSHmax = S-FSHmax, LHmax = S-LHmax, S-LHmax/S-FSHmax) using regression and correlation analyses (Spearman’s test). Furthermore, the correlations between the pubertal stages [Tanner breast stage (B), genital stage (G), pubic hair stage (PH), testicular volume] and gonadotropin concentrations were determined.

The diagnostic validity of various tests was evaluated by receiver operating characteristic (ROC) curve analysis [23] to calculate the area under the curve (AUC), sensitivity and specificity levels at various cut-off values for the differentiation of early pubertal (Tanner stage B/G 2) from prepubertal (Tanner stage B/G 1) and separately to predict the pubertal response in the GnRH stimulation test. Differences in the median gonadotropin concentrations between pubertal stages in both sexes were analyzed by the non-parametric Kruskal-Wallis test for a general overview and subsequently by the Mann-Whitney U test for adjacent pubertal stages. A p value <0.05 was considered statistically significant.

Statement of Ethics
The research protocol was approved by the Ethics Committee at Sahlgrenska University Hospital, University of Gothenburg. Informed consent was obtained from the parents.

Results
The FMV U-LH and U-FSH concentrations correlated well with the corresponding basal and GnRH-stimulated serum levels (r ≥ 0.66, p < 0.001 for all), and there was also a very strong correlation between the FMV U-LH/U-FSH and S-LHmax/S-FSHmax ratios (r = 0.80, p < 0.001) (table 1). The correlations were similar in the subgroups of prepubertal and pubertal subjects (data not shown). The correlation of U-LH and S-LH with pubertal stage (Tanner stage B/G) and testicular volume was also strong (r ≥ 0.59, p < 0.001 for all) (table 1).

Table 1. Correlation between FMV urinary gonadotropin concentrations and their ratios with the respective S-LH max and S-FSH max values in GnRH stimulation tests, as well as correlations of these values with the clinically determined pubertal stage

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>r</td>
<td>p</td>
<td>r</td>
<td>p</td>
<td>r</td>
<td>p</td>
</tr>
<tr>
<td>U-LH</td>
<td>274</td>
<td>0.78</td>
<td>&lt;0.001</td>
<td>0.78</td>
<td>&lt;0.001</td>
<td>0.50</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>S-LH</td>
<td>274</td>
<td>–</td>
<td>–</td>
<td>0.77</td>
<td>&lt;0.001</td>
<td>0.53</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>U-LH/U-FSH</td>
<td>274</td>
<td>0.59</td>
<td>&lt;0.001</td>
<td>0.60</td>
<td>&lt;0.001</td>
<td>0.80</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>U-FSH</td>
<td>274</td>
<td>0.50</td>
<td>&lt;0.001</td>
<td>0.49</td>
<td>&lt;0.001</td>
<td>n.s.</td>
<td>n.s.</td>
</tr>
<tr>
<td>Testicular volume</td>
<td>196 boys</td>
<td>0.71</td>
<td>&lt;0.001</td>
<td>0.72</td>
<td>&lt;0.001</td>
<td>0.56</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tanner stage B</td>
<td>78 girls</td>
<td>0.65</td>
<td>&lt;0.001</td>
<td>0.59</td>
<td>&lt;0.001</td>
<td>0.53</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tanner stage PH</td>
<td>260 children</td>
<td>0.47</td>
<td>&lt;0.001</td>
<td>0.56</td>
<td>&lt;0.001</td>
<td>0.39</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

n.s. = Not significant.
the pubertal GnRH test result (AUC about 0.9 for all) (table 3, lower part).

Among boys with Tanner stages 1–2, the sensitivity to detect puberty with the GnRH test was 92% at a specificity of 66% (table 4). The same sensitivity was obtained with a cut-off value of 1.48 IU/l for U-LH and of 0.05 IU/l for S-LH with an equal specificity of 67% for both methods. Among girls at Tanner stages 1–2, the sensitivity of the GnRH test to detect puberty was only 59% and the specificity 66%. For the same level of sensitivity (59%), it was possible to obtain a specificity of 96% for U-LH and of 69% for S-LH at cut-off levels of 2.60 and 0.03 IU/l, respectively (table 4). Cut-off values of 1.5 IU/l for U-LH in boys and of 1.2 IU/l in girls pro-

![Fig. 1. Distribution of S-LH_{max} concentrations (IU/l) compared to FMV U-LH concentrations (IU/l) (upper panels) and that of S-LH_{max} and FSH_{max} concentration ratios in the GnRH test compared to FMV U-LH and U-FSH concentration ratios (lower panels) in different Tanner G/B stages. The filled boxes represent boys and the open ones girls. Note the logarithmic scale of the y-axes. The lines in the boxes represent the median values, the lower and upper limits of the boxes correspond to the 25th and 75th percentiles, and the whiskers represent the 95% confidence interval limits. Outliers are plotted separately. Mild and extreme outliers are marked with a circle or asterisk, respectively.](image-url)
vided optimal sensitivity and specificity for identification of puberty. The corresponding cut-off values for S-LH would be 0.04 IU/l for boys and 0.02 IU/l for girls (table 4).

**Discussion**

The FMV U-LH concentrations correlated well with the basal S-LH levels, agreeing with previous studies in children and adolescents without endocrine disorders [13, 18, 24]. FMV U-LH also correlated very well with S-LHmax and so did the FMV U-LH/U-FSH ratio with the S-LHmax/S-FSHmax ratio. This is in line with previous studies on girls with precocious puberty: Witchel et al. [25] found a good correlation between 24-h U-LH and S-LHmax in 18 girls on GnRH analog treatment, and Zung et al. [26] between FMV U-LH and S-LHmax and the S-LHmax/S-FSHmax ratio in 47 girls with signs of precocious puberty. On the basis of the excellent correlations between the FMV U-LH and S-LHmax concentrations in this study, it is not surprising that the FMV U-LH concentrations and U-LH/U-FSH ratios correlated at least equally well as S-LHmax and the S-LHmax/S-FSHmax ratios with the pubertal developmental stage (slightly higher r values for the urine tests).

Both FMV U-LH and S-LHmax as well as the U-LH/U-FSH and S-LHmax/S-FSHmax ratios increased significantly between the prepubertal and early pubertal stage in both sexes (G1 vs. G2 and B1 vs. B2), but there was a significant overlap in all these values between these pubertal stages. Our current results are in accordance with those from earlier studies in healthy children [13, 19] and partly with those of McNeilly et al. [27], who found significant differences in U-LH concentrations and U-LH/U-FSH ratios between prepubertal and pubertal children.

**Table 2.** FMV U-LH and U-FSH concentrations (IU/l) and their ratios, and S-LH and S-LHmax concentrations (IU/l) as well as S-LHmax and S-FSHmax concentration ratios in the GnRH test

<table>
<thead>
<tr>
<th>Boys</th>
<th>G1 (n = 61)</th>
<th>p</th>
<th>G2 (n = 77)</th>
<th>p</th>
<th>G3 (n = 29)</th>
<th>n.s.</th>
<th>G4 (n = 19)</th>
<th>p</th>
<th>G5 (n = 10)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>U-LH</td>
<td>0.68</td>
<td>*</td>
<td>4.58</td>
<td>*</td>
<td>7.83</td>
<td>n.s.</td>
<td>8.66</td>
<td>n.s.</td>
<td>10.78</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–17.00)</td>
<td></td>
<td>(0.04–34.50)</td>
<td></td>
<td>(2.13–33.50)</td>
<td></td>
<td>(3.76–21.50)</td>
<td></td>
<td>(2.65–25.60)</td>
<td></td>
</tr>
<tr>
<td>U-FSH</td>
<td>3.55</td>
<td>**</td>
<td>4.76</td>
<td>n.s.</td>
<td>7.05</td>
<td>n.s.</td>
<td>10.70</td>
<td>n.s.</td>
<td>8.40</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–123.00)</td>
<td></td>
<td>(0.17–179.10)</td>
<td></td>
<td>(1.11–109.00)</td>
<td></td>
<td>(3.33–32.90)</td>
<td></td>
<td>(1.78–39.40)</td>
<td></td>
</tr>
<tr>
<td>U-LH/U-FSH</td>
<td>0.22</td>
<td>*</td>
<td>0.86</td>
<td>n.s.</td>
<td>0.94</td>
<td>n.s.</td>
<td>0.89</td>
<td>n.s.</td>
<td>1.10</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–0.98)</td>
<td></td>
<td>(0.03–6.65)</td>
<td></td>
<td>(0.19–7.45)</td>
<td></td>
<td>(0.45–3.66)</td>
<td></td>
<td>(0.34–1.54)</td>
<td></td>
</tr>
<tr>
<td>S-LH</td>
<td>0.03</td>
<td>*</td>
<td>0.18</td>
<td>**</td>
<td>0.26</td>
<td>***</td>
<td>0.40</td>
<td>n.s.</td>
<td>0.43</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–0.98)</td>
<td></td>
<td>(0.01–4.30)</td>
<td></td>
<td>(0.08–2.80)</td>
<td></td>
<td>(0.12–0.75)</td>
<td></td>
<td>(0.12–0.75)</td>
<td></td>
</tr>
<tr>
<td>S-LHmax</td>
<td>2.85</td>
<td>*</td>
<td>13.00</td>
<td>***</td>
<td>14.50</td>
<td>n.s.</td>
<td>17.00</td>
<td>n.s.</td>
<td>13.75</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–36.50)</td>
<td></td>
<td>(0.30–57.50)</td>
<td></td>
<td>(1.15–52.00)</td>
<td></td>
<td>(7.75–40.00)</td>
<td></td>
<td>(9.10–41.50)</td>
<td></td>
</tr>
<tr>
<td>S-LHmax/S-FSHmax</td>
<td>0.78</td>
<td>*</td>
<td>2.89</td>
<td>n.s.</td>
<td>2.43</td>
<td>n.s.</td>
<td>2.39</td>
<td>n.s.</td>
<td>2.88</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.07–11.62)</td>
<td></td>
<td>(0.10–10.34)</td>
<td></td>
<td>(1.00–11.60)</td>
<td></td>
<td>(1.35–10.80)</td>
<td></td>
<td>(1.07–6.50)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Girls</th>
<th>B1 (n = 24)</th>
<th>p</th>
<th>B2 (n = 28)</th>
<th>p</th>
<th>B3 (n = 20)</th>
<th>p</th>
<th>B4 (n = 6)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>U-LH</td>
<td>0.42</td>
<td>**</td>
<td>2.70</td>
<td>**</td>
<td>7.51</td>
<td>n.s.</td>
<td>9.05</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–5.64)</td>
<td></td>
<td>(0.06–20.90)</td>
<td></td>
<td>(0.26–25.10)</td>
<td></td>
<td>(0.96–16.10)</td>
<td></td>
</tr>
<tr>
<td>U-FSH</td>
<td>5.01</td>
<td>n.s.</td>
<td>8.02</td>
<td>***</td>
<td>13.30</td>
<td>n.s.</td>
<td>11.25</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(1.15–11.50)</td>
<td></td>
<td>(0.54–28.20)</td>
<td></td>
<td>(2.37–34.10)</td>
<td></td>
<td>(0.17–20.20)</td>
<td></td>
</tr>
<tr>
<td>U-LH/U-FSH</td>
<td>0.08</td>
<td>**</td>
<td>0.19</td>
<td>n.s.</td>
<td>0.54</td>
<td>n.s.</td>
<td>0.80</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–0.56)</td>
<td></td>
<td>(0.03–1.71)</td>
<td></td>
<td>(0.06–1.32)</td>
<td></td>
<td>(0.24–5.65)</td>
<td></td>
</tr>
<tr>
<td>S-LH</td>
<td>0.02</td>
<td>***</td>
<td>0.07</td>
<td>***</td>
<td>0.24</td>
<td>n.s.</td>
<td>0.45</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.01–0.70)</td>
<td></td>
<td>(0.01–1.15)</td>
<td></td>
<td>(0.03–0.93)</td>
<td></td>
<td>(0.18–0.85)</td>
<td></td>
</tr>
<tr>
<td>S-LHmax</td>
<td>2.30</td>
<td>***</td>
<td>5.98</td>
<td>n.s.</td>
<td>12.00</td>
<td>n.s.</td>
<td>15.25</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.30–12.50)</td>
<td></td>
<td>(0.01–26.00)</td>
<td></td>
<td>(0.40–26.50)</td>
<td></td>
<td>(4.90–19.50)</td>
<td></td>
</tr>
<tr>
<td>S-LHmax/S-FSHmax</td>
<td>0.38</td>
<td>**</td>
<td>1.05</td>
<td>n.s.</td>
<td>1.21</td>
<td>n.s.</td>
<td>1.88</td>
<td>n.s.</td>
</tr>
<tr>
<td></td>
<td>(0.07–6.94)</td>
<td></td>
<td>(0.01–4.24)</td>
<td></td>
<td>(0.27–4.77)</td>
<td></td>
<td>(0.81–2.65)</td>
<td></td>
</tr>
</tbody>
</table>

Figures are medians (ranges). 274 children and adolescents with designated Tanner stages are listed. The differences in hormone concentrations or their ratios between adjacent pubertal stages were analyzed by the nonparametric Kruskal-Wallis and Mann-Whitney U tests. G1–G5 = Tanner genital stages 1–5 in boys; B1–B4 = Tanner breast stages 1–4 in girls; n.s. = not significant.

*p < 0.001; **p < 0.01; ***p < 0.05.
In ROC curve analyses, the AUC values of FMV U-LH and U-LH/U-FSH for predicting clinically established puberty (Tanner stage B/G 2) were actually slightly better than those of the GnRH stimulation test parameters, especially in girls. Among girls, the sensitivity of the GnRH test to detect clinical puberty was rather low (59%) with the criteria used in this study. The U-LH concentration and the U-LH/U-FSH ratio gave higher specificity (96 and 79%, respectively) than the GnRH test (66%) at this sensitivity level.

Increasing FMV U-LH excretion is an early indicator of HPG axis activation. A substantial portion of the boys and some of the girls classified as prepubertal by Tanner staging showed evidence of biochemical pubertal activa-
Evaluation of Pubertal Disorders

First Morning Voided Urinary LH in the Evaluation of Pubertal Disorders

The fairly high rate of apparently ‘false-negative’ U-LH and GnRH test results especially in girls could possibly be caused by errors in Tanner staging or by breast development initiated by other endocrine factors than gonadotropin-induced ovarian estrogens. Indeed, even when pubertal staging is performed by an experienced pediatric endocrinologist, Tanner staging is more subjective in girls than in boys. In general, U-LH measurements worked well in the evaluation of pubertal development compared with the GnRH test. With the current cut-off values, the GnRH test appears to be reliable for identification of clinical puberty in boys but not in girls. This sex difference (low sensitivity in girls) is probably at least partly explained by ‘false’ Tanner breast stage classification in girls, i.e. interpretation of thelarche as a definite sign of puberty. It is also of note that the cut-off values of the GnRH test used here for a pubertal response were quite demanding (see discussion in [26]). Girls may need a slightly lower S-LHmax cut-off value than boys in the GnRH test. This view is indirectly also supported by the slightly lower cut-off values for U-LH in girls than boys derived from the ROC curve analyses in the present study.

Basal S-LH measurements alone are also suitable for evaluating pubertal development if blood is to be drawn for other reasons. However, the current study indicates that neither boys nor girls require S-LH measurements or GnRH tests for the initial evaluation of pubertal development. Furthermore, S-LH results in children are reliable only if the assay is sensitive enough to measure the concentrations around the cut-off values in the range 0.02–0.05 IU/l. On the basis of the somewhat higher U-LH than S-LH concentrations, a single measurement of LH in FMV urine provides reliable information about pubertal hormonal development, and it is comparable to that obtained by measuring S-LH or performing the GnRH stimulation test.

When starting to test the utility of urinary gonadotropin measurements in the evaluation of pubertal HPG axis function in early 1990s, we chose FMV urinary samples because they had mostly been used and supposed to best reflect nighttime gonadotropin secretion pulses typical for early puberty [14, 29, 30]. However, Bourguignon et al. [31] had earlier reported that urine samples collected between 8 and 12 a.m. contained somewhat unexpectedly more LH and FSH than samples collected between midnight and 4 a.m. and samples collected between 4 a.m. and 8 a.m. Thus, additional detailed studies comparing U-FSH and U-LH concentrations in first and second morning voided urinary samples from the same subjects with different pubertal stages would be well-grounded.

A potential limitation of FMV U-LH assays is the fact that a large part of LH immunoreactivity in urine consist of a fragment of the LHβ subunit called the core fragment (LHβcf) [32]. Different assays recognize this fragment to variable degrees, and therefore the measured LH concentrations are highly dependent on the assay used [33]. There are also differences in the detection limits for LH, and a reliable estimation of low prepubertal levels requires the use of a highly sensitive assay. The stability of LH in urine is also a problem if urinary samples are stored frozen; much of the LH can be degraded during long-term storage of urine at –20°C [18, 33]. When interpreting the results of this study, it is important to note that the results are based on subjects referred for investigation of different growth and pubertal disorders. This means that for example the ranges for FMV U-LH and U-FSH concentrations shown (table 2) may not be applicable as reference values for healthy unselected children. Reference values of FMV U-LH and U-FSH [24] and U-LH with the current LHspec assay [13] have been presented previously for healthy children.

We conclude that the measurement of FMV U-LH and the U-LH/U-FSH ratio can be used as a noninvasive method for the biochemical evaluation of pubertal development and its disorders, thus reducing the need for invasive GnRH stimulation tests. Determination of FMV U-LH may also be valuable for monitoring the progress and treatment of precocious puberty as recently suggested by Zung et al. [26].

Acknowledgements

The authors are grateful to the staff at the GP-GRC, especially Ann-Sofie Petersson and Carina Ankarberg-Lindgren, for both taking care of the patients and performing the laboratory analyses.
References


34. Demir/Voutilainen/Stenman/Dunkel/Albertsson-Wikland/Norjavaara